Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

BACKGROUND: We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear. METHODS: The neoadjuvant GeparQuinto tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Witzel, I, Loibl, S, von Minckwitz, G, Eidtmann, H, Fehm, T, Khandan, F, Schmatloch, S, Hauschild, M, Bischoff, J, Fasching, P A, Mau, C, Schem, C, Rack, B, Meinhold-Heerlein, I, Liedtke, C, Karn, T, Huober, J, zu Eulenburg, C, Issa-Nummer, Y, Untch, M, Müller, V
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3464767/
https://ncbi.nlm.nih.gov/pubmed/22892393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.353
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars